---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-048294"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T10:54:05.825142+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals launches generic Norco (hydrocodone/acetaminophen) tablets

## Summary
- Launched generic Norco (hydrocodone bitartrate/acetaminophen) in 2.5/325, 5/325, 7.5/325, and 10/325 mg strengths.
- Indicated for management of pain severe enough to require an opioid analgesic when alternatives are inadequate.
- IQVIA reported annual sales of approximately $300M for the brand product for 12 months ending September 2024.
- Product marketed and sold under the Elite Laboratories label.

## SEC filing metadata
- accession: 0001493152-24-048294
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315224048294/0001493152-24-048294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315224048294/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-048294
- JSON: https://secwatch.observer/filing/0001493152-24-048294.json
- Plain text: https://secwatch.observer/filing/0001493152-24-048294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.